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The limb-girdle muscular dystrophies are a group of disorders where our understanding of their underlying molecular basis has made huge
strides over the past years, revealing great heterogeneity at the clinical and molecular level. The availability of direct protein and/ or gene based
approaches to diagnosis means that these disorders can now be precisely defined, and such definition of a precise diagnosis is increasingly
allowing directed management for these diseases by the ability to predict specific complications such as those of the cardiac or respiratory systems.
An algorithm combining clinical, biochemical and molecular testing is described which will aid precision of diagnosis and direct specific testing
towards the cases most likely to benefit. This brings advantages for the patients of today in recognising the specific risks of their disorders, and in
the future will be the starting point for specific gene and protein based therapies.
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The limb-girdle muscular dystrophies are a group of
disorders which were historically grouped together because
of the shared clinical feature of predominant involvement of
the “limb-girdle” (pelvic and shoulder) musculature. These
clinical findings are not unique to the disorders within the
“LGMD” classification—disorders such as Becker muscular
dystrophy, late onset spinal muscular atrophy, myotonic
dystrophy type 2, Bethlem myopathy and Pompe's disease
may all show overlapping clinical features, and rarer disorders
such as congenital myasthenic syndromes may also need to be
considered in the differential diagnosis. Conversely, the
LGMD classification also contains genetically defined dis-
orders where there is a broad heterogeneity of presentation and
muscle involvement. This is particularly true for some of the
dominant disorders in the LGMD classification, such as
LGMD1A where myotilin mutations are associated also with
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doi:10.1016/j.bbadis.2006.09.009where lamin A/C mutations can also cause a wide range of
different diseases, and LGMD1C where the clinical presenta-
tion includes hyperCKaemia, rippling muscle disease, myalgia
and distal myopathy.
The molecular basis of the diseases is also highly hetero-
geneous. The process of gene identification in LGMD has
involved a combination of linkage and candidate gene analysis,
resulting in a gene and protein based classification which
includes three known genes causing an autosomal dominant
LGMD [1] and eleven known genes causing autosomal
recessive LGMD [2,3] (see Table 1). The genes and proteins
causing the diseases in these groups show a huge range of
localisation across the muscle fibre, from sarcolemma to nuclear
envelope, with functions ranging from structural to enzymatic.
As the current state of our understanding of the pathogenesis of
many of these disease groups is dealt with elsewhere in this
issue, this article will concentrate on the diagnostic process by
which these disorders can be defined. Such definition of a
precise diagnosis is increasingly allowing directed management
for these diseases by the ability to predict specific complications
such as those of the cardiac or respiratory systems, and in the
future will be the starting point for specific gene and protein
based therapies.
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LGMD was first designated a disease group through the
need to distinguish a set of patients with predominantly
proximal muscle weakness and a dystrophic pattern on muscle
biopsy from the more classically recognised “Duchenne/
Becker” and facioscapulohumeral muscular dystrophies, both
of which groups are much more common than LGMD. The
key hallmarks of disease remain the marked weakness of the
pelvic and shoulder girdle muscles, but as the different disease
entities within the group have become better defined based on
their distinct genetic basis, accompanying clinical features
may help to distinguish subtypes of LGMD. Particular
features which need to be sought include muscle hypertrophy
or atrophy, scapular winging, muscle rippling and contrac-
tures. While the history will in many cases be a relatively non-
specific story of progressive proximal weakness, with onset at
any age, there are some clues in the history of onset which
can be very suggestive of a particular diagnosis. This is
particularly the case in dysferlinopathy where the history of
relatively sudden onset in the late teens, often with early
inability to stand on tiptoe, and sometimes with sudden onset
of calf pain and swelling may be almost pathognomonic for
the diagnosis [4]. This group of patients in particular may be
misdiagnosed as myositis, with the inappropriate use of
steroids, to which the patients do not appear to be responsive.
In some of the autosomal dominant types of LGMD the
family history may be particularly informative. For example,
the presence in the index case or wider family of respiratory
failure, dysarthria or cardiomyopathy may help to suggest
LGMD1A [5]. History of arrhythmia or contractures can be
suggestive of laminopathy or LGMD1B [6], while a history of
muscle rippling or myalgia may be suggestive of LGMD1C
[7] (see Table 2).
3. Associated complications
Muscular dystrophies are often multisystem disorders.
Recognition of the particular type of muscular dystrophy canTable 1
The limb-girdle muscular dystrophies: classification of the entities for which the ge
Type of LGMD Gene/protein involved Protein localisation/function (if know
LGMD1A Myotilin Sarcomeric localisation
LGMD1B Lamin A/C Nuclear envelope
LGMD1C Caveolin 3 Plasma membrane, caveolae
LGMD2A Calpain 3 Cytoplasmic: proteolytic enzyme
LGMD2B Dysferlin Predominantly plasma membrane:
membrane repair
LGMD2C-F Alpha, beta, gamma,
delta sarcoglycan
Part of dystrophin glycoprotein comp
in plasma membrane
LGMD2G Telethonin Sarcomeric localisation
LGMD2H TRIM32 Ubiquitin ligase
LGMD2I FKRP Probable glycosyl transferase: substra
alpha dystroglycan
LGMD2J Titin Component of sarcomere
LGMD2K POMT1 Glycosyl transferasehelp to assign a more precise risk of complications. Complica-
tions which may be life-threatening and where appropriate
management may have a positive impact on length and quality
of life include especially those affecting the cardiovascular and
respiratory systems. These are present at different frequencies
within the various disorders in the LGMD group. Cardiovas-
cular complications may include the development of a
progressive cardiomyopathy or arrhythmias, while respiratory
complications may or may not have significant diaphragmatic
weakness as a clear component of the problem. These
complications need to be sought specifically and appropriate
management instituted for any problems detected [8,9] (see
Table 2).
4. The diagnostic process
None of the different types of LGMD can be distin-
guished on basic muscle histology or electrophysiology,
though electromyography may be useful in distinguishing
this myopathic group of diseases from myotonic dystrophy
type 2 (PROMM, DM2) which may be clinically similar, and
the muscle biopsy may be crucial in distinguishing LGMD
from Pompe's disease or other metabolic syndromes (see
Fig. 1). The serum creatine kinase is variably elevated in the
different disorders and this may serve as a useful indicator to
subdivide the different types of LGMD, though it is no more
than a guide. As a rule of thumb, the autosomal recessive
types of LGMD are typically associated with a much higher
level of creatine kinase elevation than the dominant forms of
LGMD, with the exception of LGMD1C. Diagnosis therefore
relies on a combination of clinical assessment, specialised
muscle immunoanalysis and genetic testing. In informative
families, linkage analysis may be useful to identify the gene
involved. Otherwise, protein analysis can be used to pinpoint
the likely gene primarily involved, though often complex
patterns of secondary protein involvement in addition to the
primary defect can complicate this process. A wide range of
antibodies needs to be applied and frequently both
immunolabelling of a muscle biopsy sample needs to benetic basis is known
n) Other phenotypes References
Myofibrillar myopathy [11,12]
Many [13,14,29]
Dilated cardiomyopathy [15,16]
[17,18]
Miyoshi Myopathy, distal muscular dystrophy with
anterior tibial involvement
[19,20]
lex Delta sarcoglycan: dilated cardiomyopathy [21,22]
[23]
Sarcotubular myopathy, Bardet Biedl Syndrome [24,25]
te Congenital muscular dystrophy MDC1C and
intermediate phenotypes
[26,27]
Heterozygotes have distal myopathy. Other mutations
associated with cardiomyopathy
[28]
Walker–Warburg syndrome and intermediate phenotypes [2]
Table 2
Key clinical features and complications of the limb girdle muscular dystrophies
Type of
LGMD
Age at onset Key features from history Key features from
examination
Complications Specific surveillance and
treatment
LGMD1A Usually adulthood May be dysarthria,
tight TAs, swallowing
difficulties
May be distal muscle
involvement
Cardiomyopathy,
arrhythmia, respiratory
failure
Cardiac echo, ECG +/− Holter,
FVC in sitting and lying.
Treatment with pacing, respiratory
support
LGMD1B Any age May be family history
of sudden death
Joint contractures,
rigid spine
Cardiac complications
probably invariable:
arrhythmia, subsequent
cardiomyopathy,
respiratory failure
Cardiac echo, ECG +/− Holter,
FVC in sitting and lying.
High risk of ventricular arrhythmia
after pacing so implantable
defibrillator indicated.
Medical management of
cardiomyopathy, respiratory
support
LGMD1C Any age Myalgia, muscle
rippling
PIRCs, rippling, muscle
hypertrophy
Not reported with
LGMD1C phenotype
LGMD2A Typically 2–15:
in some patients older
May present with toe
walking
Scapular winging, some
patients have contractures,
often atrophic
Not frequent
LGMD2B Most present between
17–25 years
Inability to walk on tip-toe.
Around 10% may present with
calf pain and swelling
Usually calf wasting,
biceps wasting.
Shoulder girdle
weakness usually later than
proximal/ distal lower
limb weakness
Not frequent
LGMD2C-F May present any age:
most in childhood
May present in
Duchenne/ Becker like way
May be muscle
hypertrophy, scapular
winging
Cardiomyopathy.
Respiratory failure after
confinement to
wheelchair
Cardiac echo and ECG on annual
basis, FVC particularly after loss
of ambulation, pulse oximetry.
Medical management of
cardiomyopathy, nocturnal
respiratory support
LGMD2G 2nd decade May be distal weakness Not reported
LGMD2H 2nd decade Not reported
LGMD2I Wide range of
severity
Clinically may
resemble Duchenne/
Becker MD
Muscle hypertrophy Cardiomyopathy and
respiratory failure
(diaphragmatic) possible
even while still ambulant
Cardiac echo and ECG on
annual basis,
FVC in sitting and lying at
all ages, pulse oximetry.
Medical management of
cardiomyopathy,
nocturnal respiratory support
LGMD2J 1st decade History of distal
weakness
in heterozygotes
Late respiratory
complications
LGMD2K 1st decade May present early
with global delay
May be mental retardation,
microcephaly.
Upper limb weakness may
be worse than
lower limb weakness
Full spectrum of
complications possibly
not yet appreciated
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Table 3.
Combining information from the clinical and biopsy
details therefore allows a diagnostic algorithm to be
suggested and this is presented in Fig. 1. In part 1 of the
algorithm the features which may suggest diagnosis of either
LGMD2I or LGMD1B (neither of which can be definitively
diagnosed by muscle biopsy) are described. Parts 2–4
describe the interpretation of the muscle biopsy findings
together with clinical pointers which may lead to a suggestion
of a genetic diagnosis which needs to be confirmed by
testing.5. Conclusions
Achieving a precise diagnosis in all patients will become
increasingly important as new specific therapies are developed.
The LGMDs continue to present a complex challenge for
diagnosis, but the recognition of the different subgroups within
this broad and heterogeneous classification already allows
better strategies for management and genetic counseling. As
diagnostic testing begins to be systematically applied in
different countries, the epidemiology of these diseases can
increasingly be understood, and a variable pattern of disease
frequency can be discerned. Therefore the future development
Fig. 1. A diagnostic algorithm for achieving diagnosis in LGMD based on clinical, creatine kinase, muscle biopsy and molecular genetic testing. CK=creatine kinase,
CK levels are given as a general guide to levels of CK likely at diagnosis, but this can vary from patient to patient and with disease progression. CK level A=normal or
mild elevation (<10× normal) CK level B=moderate elevation (8–40× normal) CK level C extreme elevation (>40× normal). Other abbreviations: ADEDMD—
autosomal dominant Emery Dreifuss muscular dystrophy, EDMDX—X linked Emery Dreifuss muscular dystrophy, PIRCs—percussion induced repetitive
contractions.
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take these regional differences into account. Particularly
striking is the predominance of LGMD2I due to the common
C826A mutation in Northern Europe [10], compared to aTable 3
Diagnostic features: creatine kinase and muscle biopsy findings
Disease Creatine kinase levels Histology
LGMD1A Usually normal or mild elevation Dystrophic, may be desmin
accumulation, rimmed vacu
LGMD1B Typically normal or mild elevation:
severe cases may be higher
Dystrophic
LGMD1C From 3 to 10× normal Myopathic, dystrophic
LGMD2A Often at least 10× normal Dystrophic
LGMD2B May be up to 100× normal Dystrophic, may be inflamm
features
LGMD2C-F Often at least 10× normal Dystrophic
LGMD2I Often at least 10× normal Dystrophic
LGMD2J Few cases: high CK Myopathic, dystrophic, may
be rimmed vacuoles
LGMD2K At least 10× normal Dystrophicrelatively higher proportion of LGMD2A and LGMD2B cases
in Southern Europe. A highly focussed approach to LGMD
diagnostics is already improving management and is going to
become increasingly important in the future.Primary abnormality on
immunolabelling
Secondary abnormality on
immunolabelling
oles
Myotilin may show
accumulation
↓ laminin γ1
Lamin A/C N ↓ laminin β1
↓ caveolin-3 ↓ dysferlin
Variable loss on immunoblotting
atory ↓ dysferlin (May be↓ calpain 3, and/or ↓
caveolin 3)
↓ sarcoglycans ↓ other SGs, dystrophin
FKRP antibody not in routine use ↓ laminin α2, αDG
↓ titin ↓ calpain-3
POMT1 antibody not in routine use ↓ laminin α2, αDG
242 K. Bushby et al. / Biochimica et Biophysica Acta 1772 (2007) 238–242References
[1] A. Starling, F. Kok, M.R. Passos-Bueno, M. Vainzof, M. Zatz, A new form
of autosomal dominant limb-girdle muscular dystrophy (LGMD1G) with
progressive fingers and toes flexion limitation maps to chromosome 4p21,
Eur. J. Hum. Genet. 12 (2004) 1033–1040.
[2] B. Balci, G. Uyanik, P. Dincer, C. Gross, T. Willer, B. Talim, G. Haliloglu,
G. Kale, U. Hehr, J. Winkler, H. Topaloglu, An autosomal recessive limb-
girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic
to Walker–Warburg syndrome (WWS) caused by a mutation in the
POMT1 gene, Neuromuscul. Disord. 15 (2005) 271–275.
[3] V. Nigro, Molecular bases of autosomal recessive limb-girdle muscular
dystrophies, Acta Myol. 22 (2003) 35–42.
[4] K. Nguyen, G. Bassez, R. Bernard, M. Krahn, V. Labelle, D. Figarella-
Branger, J. Pouget, H. Hammouda el, C. Beroud, A. Urtizberea, B.
Eymard, F. Leturcq, N. Levy, Dysferlin mutations in LGMD2B, Miyo-
shi myopathy, and atypical dysferlinopathies, Hum. Mutat. 26 (2005)
165.
[5] M. Olive, L.G. Goldfarb, A. Shatunov, D. Fischer, I. Ferrer, Myotilino-
pathy: refining the clinical and myopathological phenotype, Brain 128
(2005) 2315–2326.
[6] V. Decostre, R. Ben Yaou, G. Bonne, Laminopathies affecting skeletal and
cardiac muscles: clinical and pathophysiological aspects, Acta Myol. 24
(2005) 104–109.
[7] S.E. Woodman, F. Sotgia, F. Galbiati, C. Minetti, M.P. Lisanti,
Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal
dominant muscle diseases, Neurology 62 (2004) 538–543.
[8] K. Bushby, F. Muntoni, J.P. Bourke, 107th ENMC international workshop:
the management of cardiac involvement in muscular dystrophy and
myotonic dystrophy. 7th–9th June 2002, Naarden, The Netherlands,
Neuromuscul. Disord. 13 (2003) 166–172.
[9] C. Wallgren-Pettersson, K. Bushby, U. Mellies, A. Simonds, 117th ENMC
workshop: ventilatory support in congenital neuromuscular disorders—
Congenital myopathies, congenital muscular dystrophies, congenital
myotonic dystrophy and SMA (II) 4–6 April 2003, Naarden, The
Netherlands, Neuromuscul. Disord. 14 (2004) 56–69.
[10] M.L. Sveen, M. Schwartz, J. Vissing, High prevalence and phenotype–
genotype correlations of limb girdle muscular dystrophy type 2I in
Denmark, Ann. Neurol. 59 (2006) 808–815.
[11] M.A. Hauser, S.K. Horrigan, P. Salmikangas, U.M. Torian, K.D. Viles,
R. Dancel, R.W. Tim, A. Taivainen, L. Bartoloni, J.M. Gilchrist, J.M.
Stajich, P.C. Gaskell, J.R. Gilbert, J.M. Vance, M.A. Pericak-Vance, O.
Carpen, C.A. Westbrook, M.C. Speer, Myotilin is mutated in limb girdle
muscular dystrophy 1A, Hum. Mol. Genet. 9 (2000) 2141–2147.
[12] D. Selcen, A.G. Engel, Mutations in myotilin cause myofibrillar myopathy,
Neurology 62 (2004) 1363–1371.
[13] A. Muchir, G. Bonne, A.J. van der Kooi, M. van Meegen, F. Baas, P.A.
Bolhuis, M. de Visser, K. Schwartz, Identification of mutations in the gene
encoding lamin A/C in autosomal dominant limb girdle muscular
dystrophy with atrioventricular conduction disturbances (LGMD1B),
Hum. Mol. Genet. 9 (2000) 1453–1459.
[14] S. Benedetti, L. Merlini, Laminopathies: from the heart of the cell to the
clinics, Curr. Opin. Neurol. 17 (2004) 553–560.
[15] T. Hayashi, T. Arimura, K. Ueda, H. Shibata, S. Hohda, M. Takahashi, H.
Hori, Y. Koga, N. Oka, T. Imaizumi, M. Yasunami, A. Kimura,
Identification and functional analysis of a caveolin-3 mutation associated
with familial hypertrophic cardiomyopathy, Biochem. Biophys. Res.
Commun. 313 (2004) 178–184.
[16] C. Minetti, F. Sotgia, C. Bruno, P. Scartezzini, P. Broda, M. Bado, E.
Masetti, M. Mazzocco, A. Egeo, M.A. Donati, D. Volonte, F. Galbiati, G.
Cordone, F.D. Bricarelli, M.P. Lisanti, F. Zara, Mutations in the caveolin-3gene cause autosomal dominant limb-girdle muscular dystrophy, Nat.
Genet. 18 (1998) 365–368.
[17] I. Richard, O. Broux, V. Allamand, F. Fougerousse, N. Chiannilkulchai, N.
Bourg, L. Brenguier, C. Devaud, P. Pasturaud, C. Roudaut, et al.,
Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular
dystrophy type 2A, Cell 81 (1995) 27–40.
[18] A. Saenz, F. Leturcq, A.M. Cobo, J.J. Poza, X. Ferrer, D. Otaegui, P.
Camano, M. Urtasun, J. Vilchez, E. Gutierrez-Rivas, J. Emparanza, L.
Merlini, C. Paisan, M. Goicoechea, L. Blazquez, B. Eymard, H.
Lochmuller, M. Walter, C. Bonnemann, D. Figarella-Branger, J.C. Kaplan,
J.A. Urtizberea, J.F. Marti-Masso, A. Lopez de Munain, LGMD2A:
genotype–phenotype correlations based on a large mutational survey on
the calpain 3 gene, Brain 128 (2005) 732–742.
[19] R. Bashir, S. Britton, T. Strachan, S. Keers, E. Vafiadaki, M. Lako, I.
Richard, S. Marchand, N. Bourg, Z. Argov, M. Sadeh, I. Mahjneh, G.
Marconi, M.R. Passos-Bueno, S. Moreira Ede, M. Zatz, J.S. Beckmann, K.
Bushby, A gene related to Caenorhabditis elegans spermatogenesis factor
fer-1 is mutated in limb-girdle muscular dystrophy type 2B, Nat. Genet. 20
(1998) 37–42.
[20] J. Liu, M. Aoki, I. Illa, C. Wu, M. Fardeau, C. Angelini, C. Serrano, J.A.
Urtizberea, F. Hentati, M.B. Hamida, S. Bohlega, E.J. Culper, A.A. Amato,
K. Bossie, J. Oeltjen, K. Bejaoui, D. McKenna-Yasek, B.A. Hosler, E.
Schurr, K. Arahata, P.J. de Jong, R.H. Brown Jr., Dysferlin, a novel skeletal
muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular
dystrophy, Nat. Genet. 20 (1998) 31–36.
[21] L.E. Lim, K.P. Campbell, The sarcoglycan complex in limb-girdle
muscular dystrophy, Curr. Opin. Neurol. 11 (1998) 443–452.
[22] S. Tsubata, K.R. Bowles, M. Vatta, C. Zintz, J. Titus, L. Muhonen, N.E.
Bowles, J.A. Towbin, Mutations in the human delta-sarcoglycan gene in
familial and sporadic dilated cardiomyopathy, J. Clin. Invest. 106 (2000)
655–662.
[23] E.S. Moreira, T.J. Wiltshire, G. Faulkner, A. Nilforoushan, M. Vainzof,
O.T. Suzuki, G. Valle, R. Reeves, M. Zatz, M.R. Passos-Bueno, D.E.
Jenne, Limb-girdle muscular dystrophy type 2G is caused by mutations
in the gene encoding the sarcomeric protein telethonin, Nat. Genet. 24
(2000) 163–166.
[24] B.G. Schoser, P. Frosk, A.G. Engel, U. Klutzny, H. Lochmuller, K.
Wrogemann, Commonality of TRIM32 mutation in causing sarcotubular
myopathy and LGMD2H, Ann. Neurol. 57 (2005) 591–595.
[25] P. Frosk, T. Weiler, E. Nylen, T. Sudha, C.R. Greenberg, K. Morgan, T.M.
Fujiwara, K. Wrogemann, Limb-girdle muscular dystrophy type 2H
associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene,
Am. J. Hum. Genet. 70 (2002) 663–672.
[26] M. Brockington, D.J. Blake, P. Prandini, S.C. Brown, S. Torelli, M.A.
Benson, C.P. Ponting, B. Estournet, N.B. Romero, E. Mercuri, T. Voit, C.
A. Sewry, P. Guicheney, F. Muntoni, Mutations in the fukutin-related
protein gene (FKRP) cause a form of congenital muscular dystrophy with
secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-
dystroglycan, Am. J. Hum. Genet. 69 (2001) 1198–1209.
[27] M. Brockington, Y. Yuva, P. Prandini, S.C. Brown, S. Torelli, M.A.
Benson, R. Herrmann, L.V. Anderson, R. Bashir, J.M. Burgunder, S.
Fallet, N. Romero, M. Fardeau, V. Straub, G. Storey, C. Pollitt, I. Richard,
C.A. Sewry, K. Bushby, T. Voit, D.J. Blake, F. Muntoni, Mutations in the
fukutin-related protein gene (FKRP) identify limb girdle muscular
dystrophy 2I as a milder allelic variant of congenital muscular dystrophy
MDC1C, Hum. Mol. Genet. 10 (2001) 2851–2859.
[28] B. Udd, A. Vihola, J. Sarparanta, I. Richard, P. Hackman, Titinopathies and
extension of the M-line mutation phenotype beyond distal myopathy and
LGMD2J, Neurology 64 (2005) 636–642.
[29] K.J. Roux, B. Burke, Nuclear envelope defects in muscular dystrophy,
Biochim. Biophys. Acta 1772 (2007) 118–127.
